Method for treatment of recurrent vulvovaginal candidiasis

FIELD: medicine.

SUBSTANCE: immunomodulatory therapy is administered by local action on the cervico-vaginal area with a drug containing sodium aminodihydrophthalazinedione, represented by the rectal suppositories Galavit, by introduction into the cervico-vaginal zone in successive doses of 100 mg overnight in three steps: the first preparatory phase of recovery of functional metabolic activity of cervical secret neutrophilic granulocytes by stimulation of their microbicidal activity by daily administration of the said drug with a course of 5 doses, one dose per day; the second stage of normalization of the monocyte-macrophagal system in the cervico-vaginal zone by enhancing phagocytosis using this drug with a course of 5 doses at a single dose with 48 hours pauses between them; the third stage of formation of a stable immune response in the cervico-vaginal zone at the local level by introduction of this drug with a course of 10 doses at a single dose with 72 hours pauses, and administration of a systemic antimycotic, which is itraconazole administered orally at a dose of 200 mg 1 dose daily, is performed at the third stage, starting with the administration of the 15th dose of Galavit.

EFFECT: normalization of the local immune status, with preservation of a full-fledged immune response in the long-term period, a stable immunity is provided, with a reduction in the number of relapses and a reduction in the duration of treatment.

3 cl, 2 tbl, 2 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to gynaecology, and can be used for a method of prevention and/or treatment of urogenital atrophy in women, including the vaginal introduction of pharmaceutical compositions with estriol, as well as for the application of estriol in the production of a pharmaceutical composition with a possibility of self-restriction of estriol absorption. The said women have the high possibility of development of a cardiovascular pathology, or suffer or suffered from the cardiovascular pathology. Estriol is introduced in a dose, smaller or equal to 0.1 mg/day. An area under the estriol concentration curve depending on the time constitutes less than 500 pg/ml·h after the introduction of repeated doses one time per day for the time period from 1 to 4 weeks.

EFFECT: group of inventions provides efficient and safe treatment.

24 cl, 7 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: presented egg-shaped vaginal suppositories contains the following mass ratio in 1 capsule (egg-shaped vaginal suppository): sulphadimine 0.05 g; metronidazole 0.01 g, potato starch 0.02 g, glucose 0.04 g, 5% polyvinyl alcohol 0.07 g, 15% oily extract of propolis 1.0 g; gelatine 0.2 g; dimethicone 0.04 g; glycerol 0.4 g; purified water 0.37 g.

EFFECT: using the invention increases the therapeutic effect and bioavailability of the capsules, increases the prolonged action time, provides the control release of the active substances.

3 cl, 1 dwg, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a topical composition containing a combination of natural salt or pure sodium chloride and glucose mixed in ratio 1:1-30 (wt/wt) as an active ingredient in an amount effective for treating bacterial vaginosis caused by Cardnerella vaginalis together with a pharmaceutically acceptable carrier.

EFFECT: invention provides the higher pharmacological activity.

4 cl, 4 ex, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness (versions). Homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness, contain Sea buckthorn oil, homeopathic oil extract, thuya oil, melaleuca oil, juniper oil, homeopathic essence of eucalyptus, homeopathic essence of elder flower, homeopathic essence of wormwood, thick extract of galium, thick extract of cimicifuga, base, taken in specified quantity. Homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness, containing Sea buckthorn oil, homeopathic oil extract, valerian oil, Melissa oil, Humulus lupulus oil, homeopathic essence of Viscum album, homeopathic essence of jaborandi, thick extract of galium, thick extract of cimicifuga, base, taken in specifies quantity. Homeopathic suppositories for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness, containing homeopathic oil extract, beggar-ticks oil, homeopathic essence of lycopodium, homeopathic essence of cantharis, thick extract of galium, thick extract of cimicifuga, base, taken in specified quantity.

EFFECT: suppositories are efficient for treatment of fungal colpitis, vulvovaginitis, endometriosis, papillomas, cervical erosion, candidosis and vaginal dryness.

3 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to a method for preparing a therapeutic hydrogel material involving mixing an aqueous solution of sodium alginate and a drug preparation, dispersing a cross-linking agent that is presented by calcium sulphate in glycerol in the concentration of 0.8-2.5%, mixing the dispersion with the prepared mixture of sodium alginate with the drug preparation in ratio 1-2:4-6, placing the prepared product into a tiling pattern and keeping it till form-stable, conducting gamma sterilisation; the formation process involves the mechanical stability measurements with the diametral compression of the formed hydrogel; the hydrogel is considered to be formed once a thickness of the formed hydrogel varies with the diametral compression by 10-30%.

EFFECT: invention provides the wider medical variation of the drug concentrations, preparing high-thixotropy soft hydrogel materials (tablets) easy to administer, including through rectum, preparing the materials that preserve its all their physical-technical and mechanical properties after the gamma sterilisation along with the sterility.

4 cl, 10 ex

FIELD: biotechnologies.

SUBSTANCE: group of inventions refers to microbiology and biotechnology. Proposed strains Lactobacillus crispatus "ВКМ" B-2727D, Lactobacillus gasseri "ВКМ" B-2728D and Lactobacillus plantarum "ВКМ" B-2731D have antagonistic activity in relation to pathogenic and semi-pathogenic microorganisms. Besides, the invention proposes a consortium based on the above strains for production of a bacterial preparation, a biologically active additive, and direct inoculation for obtaining fermented milk product of functional nutrition.

EFFECT: consortium has higher antagonistic activity against pathogenic and semi-pathogenic microorganisms in relation to individual strains of lactobacilli, use of a consortium will allow enlarging the range of devices intended for prophylaxis and treatment of urogenital infections of females.

4 cl, 1 dwg, 7 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: what is presented is using oestriol for preparing a pharmaceutical dosage form for the vaginal administration of oestriol in a dose of 0.1 mg/day or less for preventing and/or treating urogenital atrophy in females prone to a high probability of the development of oestrogen-dependent tumour or the patients suffering or suffered from oestrogen-dependent tumour.

EFFECT: it is shown that oestriol has the limited absorption from the declared dosage form that reduces its systemic exposure as compared to the control preparation that is "Ovestinon®" cream containing oestriol 0,1% with the effective elimination of vaginal atrophy.

24 cl, 1 dwg, 7 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition for local application for treating vaginitis of various origins and related inflammatory inflammations. The above composition contains benzophenanthridine alkaloids, benzofuran compounds and optionally Zanthoxylum bimgeanum or Echinacea angustifolia extract.

EFFECT: composition possesses antibacterial, antifungal and antienzymic activity and reduces vaginal infections fast, eliminates the presence of saprophytes, relieves inflammation, itch and vaginal pH.

12 cl, 3 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a composition for oral hygiene and for treating and preventing pathological conditions related to the dentofacial system, implants and complications following the oral surgeries. The above composition contains benzophenanthridine alkaloids, benzofuran compounds and catechine polyphenols.

EFFECT: composition possesses antibacterial, antifungal and antienzymic activity that exceeds total activities of the different ingredients if used separately.

14 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology and may be used for individual selection of the preparations containing the probiotic lactic bacterial strains for effective intravaginal therapy. For this purpose, vaginal epithelial cells are recovered from the patient, released from the accompanying microflora. That is followed by preparing an epithelial cell suspension in a culture medium, and mixed with a suspension of thermally-activated probiotic lactic bacterial strains. Then, the suspension is incubated; the epithelial cell culture fluid filtrate is prepared and added to the suspension of the tested probiotic lactic bacterial strains in ratio 1:7. Concurrently, a reference of the mixture of the epithelial cell culture medium and the suspension of the tested probiotic lactic bacterial strains in ratio 1:7 is prepared. The test and reference samples are incubated, measured for optical density; and a degree of biomass increase in the test sample is related to that in the reference. The preparation containing the probiotic lactic bacterial strains the biomass increase of which under the influence of patient's vaginal epithelial cells is stimulated most is selected form the effective intravaginal therapy.

EFFECT: invention enables the individual selection of the preparations containing the probiotic lactic bacterial strains for the effective intravaginal therapy.

3 ex, 1 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new chemical compounds of general formula I wherein LA, LB, LC, cycle A, cycle B, RA, RB, RC, RD, RE and RF have the values specified in the patent claim. The compounds of formula (I) are protein kinase inhibitors.

EFFECT: invention refers to pharmaceutical compositions containing the above compounds, as well as to using the above compounds for treating and/or preventing the diseases related to aberrant protein kinase activity, particularly oncological diseases.

10 cl, 14 tbl, 25 ex

FIELD: medicine.

SUBSTANCE: present invention refers to compounds having formula III such as below, wherein: Q represents C(Y3) or N; R represents H, -R1, -R1-R2-R3, -R1-R3 or -R2-R3; R1 represents heteroaryl or heterocyclyl each of which is optionally substituted by one or more C1-6alkyls, hydroxyC1-6alkyls, oxogroups or halogenC1-6alkyls; R2 represents -C(=O), -O, -C(R2')2, -C(R2')2C(=O), -C(R2')2C(=O)NR2', C(R2')2 N(R2')C(=O), -C(=NH), -C(R2')2NR2' or -S(=O)2; each R2' independently represents H or C1-6alkyl; R3 represents H or R4; R4 represents C1-6alkyl, C1-6alkoxygroup, aminogroup, C1-6alkylaminogroup, di(C1-6alkyl)aminogroup, heterocyclyl, C1-10alkylheterocycloalkyl, heterocycloalkylC1-10alkyl each of which is optionally substituted by one or more C1-6alkyls, C1-6alkylaminogroups, di(C1-6alkyl)aminogroups, hydroxygroups, hydroxyC1-6alkyls, C1-6alkoxygroups, oxogroups or halogenC1-6alkyls; X represents CH; X' represents CH; and the rest symbols have values as specified in the patent claim. The compounds of formula III inhibit Bruton's tyrosine kinase (Btk). There are also described compositions containing the compounds of formula III, and at least one carrier, thinner or excipient, and a method for producing the compound of formula X in accordance with the following procedure.

EFFECT: compositions are effective for modulating Btk activity and treating diseases related to Btk hyperactivity, and can be used for treating inflammatory and autoimmune diseases related to disturbed B-cell proliferation, such as rheumatoid arthritis.

22 cl, 2 tbl, 260 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula , wherein A represents CRaRb or -CH2-CH2-; R1 represents hydrogen or alkyl; R2 represents hydrogen or alkyl; R3 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl, substituted aryl, 1H-pyrazolyl or substituted 1H-pyrazolyl, wherein substituted aryl represents aryl substituted by 1-3 substitutes independently specified in alkyl, halogen and halogenalkyl, and wherein substituted 1H-pyrazolyl represents 1H-pyrazolyl substituted by 1-3 substitutes independently specified in alkyl and aryl; Ra represents hydrogen or methyl; Rb represents hydrogen or methyl; or Ra and Rb together with a carbon atom, to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl; provided Ra and Rb both represent hydrogen, or both represent methyl simultaneously, R3 represents (1-methylcyclopropyl)methyl, which possess the inhibitory action on 11b-HSD1.

EFFECT: preparing the compounds, which possess the inhibitory action on 11b-HSD1.

15 cl, 1 tbl, 32 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to field of organic chemistry, namely to novel compound of formula (I), where Y and Z, each independently, are selected from group, consisting of: a) phenyl, if necessary substituted with 1 or 2 R6; b) pyridine, imidazole, thiazole, furan, triazole, quinoline or imidazopyridine, if necessary substituted with 1 R6; and c) substituent, independently selected from group, consisting of hydrogen, C1-C6alkyl or pyperidine; R1, R2 and R3, each independently selected from group, consisting of hydrogen and halogen; A and B is each independently selected from hydrogen, OH and C1-C6alkyl; RA and RB are independently selected from group, consisting of hydrogen, C1-C6alkyl and C3-C8cycloalkyl; or RA and RB together with atom, to which they are attached, form 4-6-membered heterocycle, if necessary having additionally one heteroatom or functional heterogrpoup, selected from group, consisting of -O-, -NH, -N(C1-C6-alkyl)- and -NCO(C1-C6-alkyl)-, and 6-membered heterocycle can be additionally substituted with one or two C1-C6-alkyl groups; R4 and R5, each stands for hydrogen; and each R6 is selected from Br, Cl, F, I, C1-C6-alkyl, pyrrolidine, if necessary substituted with one C1-C6-alkyl, C1-C6alkoxy, halogen-C1-C6alkyl, hydroxyl-C1-C6alkylene, -(NRARB)C1-C6alkylene and (NRARB)carbonyl; or to its individual isomer, stereoisomer or enantiomer, or their mixture, if necessary pharmaceutically acceptable salt. Invention also relates to compound of formula (II), particular compounds of formula (I) and (II), pharmaceutical composition and industrial product based on compound of formula (I) and (II), method of treating said pathological conditions, method of obtaining formula (I) compound and to intermediate compound of formula 3.

EFFECT: novel compounds, useful as inhibitors of poly(ADP-ribose)polymerase, are obtained.

50 cl, 1 tbl, 159 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of novel pyrrolopyrazine derivatives of formula , where variables Q and R are as defined in the claim, which inhibit JAK and SYK.

EFFECT: high effectiveness when treating autoimmune and inflammatory diseases.

11 cl, 59 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel pyridin-2-one and pyridazin-3-one derivatives, having Btk inhibiting activity. In formulae I-IV:

,

R denotes -R1-R2-R3 or -R2-R3; R1 denotes a heteroaryl containing 6 ring atoms, including one N heteroatom; R2 denotes -C(=O), -C(=O)N(R2'), where R2' denotes H; R3 denotes R4; where R4 is a lower alkyl, heterocycloalkyl, (lower alkyl) heterocycloalkyl or heterocycloalkyl (lower alkyl), where the heterocycloalkyl contains 6 ring atoms, including two heteroatoms selected from N and O; and where R4 can be substituted with one or more substitutes selected from lower alkyl, oxo group and lower alkoxy group; X denotes CH or N; Y1 denotes lower alkyl; n and m are equal to 0; values of radicals Y2, Y4 are given in the claim.

EFFECT: improved properties of compounds.

6 cl, 2 tbl, 42 ex

FIELD: chemistry.

SUBSTANCE: described are novel triazolopyridazines of general formula , stereoisomeric or tautomeric forms thereof and physiologically acceptable salts thereof, where Q1 denotes H, -C1-6alkyl, optionally substituted with fluorine, or -C3-6cycloalkyl; Q2 and Q3 independently denote H, -C1-6alkyl; R1-R3 independently denote H, -C1-6 alkyl, -C3-6cycloalkyl, -O-C3-6cycloalkyl, -O-C1-8alkyl, a heterocyclic residue etc; R4-R8 independently denote H, -C1-6 alkyl, -OH, -O-C1-8 alkyl, halogen, SF5 etc, a method for production thereof and use as medicinal agents.

EFFECT: compounds have antithrombotic activity and particularly inhibit the protease-activated receptor.

6 cl, 2 tbl, 242 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically dermatology, and may be used for treating the patients with psoriatic erythroderma. For this purpose, detoxification hormone therapy combined with external ointment therapy is preceded by prescribing Galavit in a therapeutic dose of 100 mg intramuscularly every day within the course of 10 procedures.

EFFECT: method provides higher clinical effectiveness ensured by a shorter length of therapy, no side effects and prolonged remission.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: present invention describes compounds of formula I: wherein: X1 and X2 independently represent CH or N; R1 represents fluorine or hydrogen; R2 represents hydrogen, halogen; Ar represents phenyl substituted by 1-3 groups optionally substituted in each specific case in a group consisting of hydrogen, halogen, cyano group; R3 is independently specified in each specific case in a group consisting of: (i) CH2OH; (ii) CH2O-C(=O)(CH2)nCO2R4, wherein n has a value of 2 to 5; (iii) CH2O-C(=O)CH2OCH2CO2R4; (iv) CH2OCOR5; (v) CH2OC(=O)CHR6NH2; (vi) C(=O)R5, and (vii) CH2OP(=O)(OH)2; R4 represents hydrogen or C1-10 alkyl; R5 represents hydrogen or C1-10 alkyl, C1-3 dialkylamino-C1-10 alkyl, C1-6 alkoxy or pyridinyl, R6 represents C1-6 alkyl or a side chain of a natural amino acid; or a pharmaceutically acceptable salt thereof. Besides, the invention describes a pharmaceutical composition having HTVRT inhibitory activity and containing a compound according to cl.1.

EFFECT: there are prepared and described new compounds inhibiting HIV-1 reverse transcriptase and effective for preventing and treating HIV-1 infections and treating AIDS or ARC.

13 ex, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to thienopyridazine compounds of formula (I) and to pharmaceutically acceptable salts and hydrates thereof, wherein R1 and R2 independently mean H or C1-4 alkyl; R3 means a saturated or unsaturated 5- or 6-members ring containing N, S or O, or optical isomers thereof, R4 means phenyl, monosubstituted or disubstituted halogen. The invention also refers to a method for preparing the above compounds and to a pharmaceutical composition for treating and preventing tumour diseases containing the above compounds.

EFFECT: there are prepared new compounds that may be used in medicine for treating anti-tumour diseases, particularly cancer.

12 cl, 3 tbl, 19 ex

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry, specifically to bensyl aralkyl ether of formula or to its pharmaceutically acceptable salt, where: Ar represents imidazolil; R1, R2, R4 and R5 independently stand for hydrogen; R3 stands for a halogen; R6 stands for trifluoromethyl or trichloromethyl; n is an integer from 0 to 2; and m is 1. The invention also relates to the use of the compound of formula (1) for the treatment and/or prevention of diseases caused by fungi, or bacteria.

EFFECT: obtained new heterocyclic compounds with useful biological properties.

4 cl, 4 dwg, 9 tbl, 8 ex

Up!